000157225 001__ 157225
000157225 005__ 20240229123132.0
000157225 0247_ $$2doi$$a10.1002/cncr.33096
000157225 0247_ $$2pmid$$apmid:32697345
000157225 0247_ $$2ISSN$$a0008-543X
000157225 0247_ $$2ISSN$$a1045-7410
000157225 0247_ $$2ISSN$$a1097-0142
000157225 0247_ $$2ISSN$$a1934-662X
000157225 0247_ $$2ISSN$$a1934-6638
000157225 0247_ $$2altmetric$$aaltmetric:86314113
000157225 037__ $$aDKFZ-2020-01495
000157225 041__ $$aeng
000157225 082__ $$a610
000157225 1001_ $$0P:(DE-He78)62b0f1b5eccef2b5f2e55b7f13ccde6d$$aXu, Xing$$b0$$eFirst author$$udkfz
000157225 245__ $$aRisk of invasive prostate cancer and prostate cancer death in relatives of patients with prostatic borderline or in situ neoplasia: A nationwide cohort study.
000157225 260__ $$aNew York, NY$$bWiley-Liss$$c2020
000157225 3367_ $$2DRIVER$$aarticle
000157225 3367_ $$2DataCite$$aOutput Types/Journal article
000157225 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1614241454_19788
000157225 3367_ $$2BibTeX$$aARTICLE
000157225 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157225 3367_ $$00$$2EndNote$$aJournal Article
000157225 500__ $$a2020 Oct 1;126(19):4371-4378#EA:C120#LA:C120#
000157225 520__ $$aThe question of whether having a family history of prostatic borderline or in situ neoplasia (PBISN) is associated with an increased risk of invasive prostate cancer (PCa) or death from PCa remains unanswered. The objective of the current study was to provide an evidence-based risk estimation for the relatives of patients with PBISN.Nationwide Swedish family cancer data sets were used for the current study, including data regarding all residents of Sweden who were born after 1931 and their parents. Standardized incidence ratios (SIRs), standardized mortality ratios (SMRs), and lifetime cumulative risks of PCa were calculated for men with different constellations of family history. Family history was defined as a dynamic (time-dependent) variable considering changes during follow-up (1958-2015).Of the 6,343,727 men in the current study, a total of 238,961 developed invasive PCa and 5756 were diagnosed with PBISN during the follow-up. Men with 1 first-degree relative who was diagnosed with PBISN had a 70% increased risk of invasive PCa (SIR, 1.7; 95% confidence interval, 1.5-1.9) and PCa death (SMR, 1.7; 95% confidence interval, 1.3-2.2) compared with men with no family history of PBISN or invasive PCa. These were rather close to estimates in men with 1 first-degree relative diagnosed with invasive PCa (SIR, 2.1 and SMR, 1.8). A higher risk of PCa in family members was found among patients with a family history of PBISN and/or PCa diagnosed before age 60 years. The results in terms of cumulative risk resembled this trend.A family history of PBISN appears to be as important as a family history of invasive PCa with regard to an increased risk of invasive PCa or PCa mortality. Such a history should not be overlooked in PCa screening recommendations or in future research regarding familial PCa.
000157225 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000157225 588__ $$aDataset connected to CrossRef, PubMed,
000157225 7001_ $$0P:(DE-He78)b510b884502b619724039bf33fdae68a$$aFallah, Mahdi$$b1$$udkfz
000157225 7001_ $$0P:(DE-He78)834e8bc4d74592e3b999100c157215f5$$aTian, Yu$$b2$$udkfz
000157225 7001_ $$0P:(DE-He78)ef3f7c40c2c68936a43baab29d559371$$aMukama, Trasias$$b3$$udkfz
000157225 7001_ $$aSundquist, Kristina$$b4
000157225 7001_ $$aSundquist, Jan$$b5
000157225 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b6$$udkfz
000157225 7001_ $$0P:(DE-He78)e56510c7dedbff7a279ad76dad80eeda$$aKharazmi, Elhamalsadat$$b7$$eLast author$$udkfz
000157225 773__ $$0PERI:(DE-600)1479932-7$$a10.1002/cncr.33096$$gp. cncr.33096$$n19$$p4371-4378$$tCancer$$v126$$x0008-543X$$y2020
000157225 909CO $$ooai:inrepo02.dkfz.de:157225$$pVDB
000157225 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)62b0f1b5eccef2b5f2e55b7f13ccde6d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000157225 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b510b884502b619724039bf33fdae68a$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000157225 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)834e8bc4d74592e3b999100c157215f5$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000157225 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ef3f7c40c2c68936a43baab29d559371$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000157225 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000157225 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e56510c7dedbff7a279ad76dad80eeda$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000157225 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000157225 9141_ $$y2020
000157225 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2020-08-28$$wger
000157225 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER-AM CANCER SOC : 2018$$d2020-08-28
000157225 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-28
000157225 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-28
000157225 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-08-28
000157225 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-08-28
000157225 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-28
000157225 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-08-28
000157225 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-28
000157225 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-08-28
000157225 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-08-28
000157225 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-08-28
000157225 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-28
000157225 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-28
000157225 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER-AM CANCER SOC : 2018$$d2020-08-28
000157225 9202_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000157225 9200_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000157225 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000157225 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000157225 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000157225 980__ $$ajournal
000157225 980__ $$aVDB
000157225 980__ $$aI:(DE-He78)C120-20160331
000157225 980__ $$aI:(DE-He78)C070-20160331
000157225 980__ $$aI:(DE-He78)HD01-20160331
000157225 980__ $$aUNRESTRICTED